Novartis says ‍revolade shows long-term disease control for chronic/persistent immune thrombocytopenia * Mareeg.com somalia, World News and Opinion.
Mareeg Media
Somalia

Novartis says ‍revolade shows long-term disease control for chronic/persistent immune thrombocytopenia

ZURICH (Reuters) – Novartis said on Wednesday a long term study of ‍its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) – a condition where patients’ blood does not clot normally.

Patients with ITP, which is caused by a low number of platelets, suffer bruising, bleeding and in some cases can even bleed to death.

The study showed platelet counts were elevated within two weeks of using Revolade treatment, with reduced overall bleeding, Novartis said.

(Reporting by John Revill)

Get real time updates directly on you device, subscribe now.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Do NOT follow this link or you will be banned from the site!